Novimmune Completes CHF30 Million ($29.8 Million) Funding Round with Existing Shareholders

Broad Participation from Shareholder Base to Invest in Developing the Drug Pipeline, Including NI-0501 for Hemophagocytic Lymphohistiocytosis (HLH)

GENEVA, 11th January, 2016 — Novimmune, a Swiss biotech company focused on the discovery and development of antibody-based drugs for the targeted treatment of inflammatory and rare diseases, immune-related disorders and cancer, today announced it has completed a CHF30 million ($29.8 million) funding round.

“We are delighted to have completed a CHF30 million funding round driven by major commitments from our lead investors that secured broad participation from our existing shareholder base,” said Novimmune Chairman and Chief Executive Officer Eduard Holdener. “This support from our shareholders demonstrates the confidence they have in the strength of our pipeline and in the future of the Company. We remain committed to further developing novel medicines to provide improved treatment options for patients suffering from rare and devastating diseases like Hemophagocytic Lymphohistiocytosis (HLH), as well as autoimmune and inflammatory diseases, and cancer.”

About Novimmune

Novimmune SA is a privately held, Swiss biopharmaceutical company focused on the discovery and development of antibody-based drugs for the targeted treatment of inflammatory diseases, immune-related disorders, and cancer. The company is headquartered in Geneva. More information is available on the company website at www.novimmune.com.

Contact:

Eduard Holdener
+41 22 839 71 41
eholdener@novimmune.com

Novimmune SA

14 Chemin des Aulx
1228 Plan-Les-Ouates
Geneva, Switzerland
+41 22 839 71 41 Tel
+41 22 839 71 43 Fax
www.novimmune.com